to-BBB starts manufacturing collaboration with TTY Biopharm for brain cancer treatment
TTY Biopharm will become a co-development partner of to-BBB for the manufacturing of brain-targeted doxorubicin liposomes. These liposomes are essential for the clinical development of to-BBB’s lead product for the treatment of brain cancer.
Werner Gladdines, Head of Clinical Operations at to-BBB, is very pleased with this agreement: “TTY Biopharm is highly specialized in the preparation of doxorubicin PEG-liposomes and will thus be able to efficiently manufacture brain-targeted doxorubicin liposomes with the same precision within a short timeframe. Working with TTY Biopharm, therefore, greatly accelerates our clinical development of our lead product for brain cancer”.
Based on its proprietary G-Technology, discovered by the Industrial Technology Research Institute (ITRI) in Taiwan, to-BBB is developing its lead compound, brain-targeted doxorubicin liposomes. These liposomes are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery of free drug to the brain. Doxorubicin glutathione-PEG liposomes have shown a reduced brain tumor growth in proof-of-concept studies, which provides a strong basis for clinical development. For this development, to-BBB requires clinical scale batches of the brain-targeted doxorubicin liposomes, produced according to cGMP standards. TTY Biopharm will provide these liposomes in a timely manner.
to-BBB announced the successful finalization of a round C financing of €10 million with new and existing investors. The company also announced the appointment of Dr. Pericles (Perry) Calias as Senior Vice President Translational Medicine and the appointment of Leonard Kruimer as interim CEO ... more
to-BBB announced the addition of Dr. Peter Høngaard Andersen to its Supervisory Board. Dr. Andersen brings many years of pharma drug development experience to the Board. His experience and strategic guidance will be instrumental to further build to-BBB as a leading company in brain drug dev ... more
The ALS Therapy Development Institute (ALS TDI) announced that it has entered into a new collaboration with to-BBB to investigate potential treatments for ALS (aka Motor Neuron or Lou Gehrig’s disease).
The blood-brain barrier (BBB) fortifies the walls of blood vessels to prevent the entry ... more
to-BBB is a Dutch biotechnology company in the field of brain-targeted drug delivery which uses its platform technologies to synergize with established and marketed drugs. to-BBB’s vision is that the treatment of currently unserved brain diseases will be best achieved by targeting to endoge ... more